Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRT13722 in HR+/HER2- Breast Cancer
NCT07905001Phase 1Not yet recruiting
- Sponsor
- Prelude Therapeutics
- Start
- Oct 2026
- Primary completion
- Oct 2028
01
Overview
Phase 1, open-label trial of PRT13722 in breast cancer (4 arms), sponsored by Prelude Therapeutics. Primary endpoints: Dose Limiting Toxicity at 28 days, Treatment-Emergent Adverse Events at 2 years and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
PRT13722
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07905001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07905001.